Influence of IFNγ co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy

Human Vaccines

Volumn 3, Issue 6, 2007, Pages 260-267

  Emery, Sean ^a   Kelleher, Anthony D ^a   Workman, Cassy ^b   Puls, Rebekah L ^a   Bloch, Mark ^c   Baker, David ^d   Anderson, Jonathan ^e   Hoy, Jennifer ^f   Ip, Susanna ^a   Nalliah, Kellie ^a   Ward, Larry D ^g   Law, Matthew G ^a   Cooper, David A ^a,h  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Ground Zero Medical Centre   (Australia)

^c Holdsworth House Medical Practice   (Australia)

^d 407 Doctors ^*  (Australia)

^e Carlton Clinic   (Australia)

^f ALFRED HOSPITAL   (Australia)

^g Virax Development Pty Ltd   (Australia)

^h ST VINCENT S HOSPITAL   (Australia)

Author keywords

HIV; Pox virus vector vaccine; Therapeutic vaccine

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; POL PROTEIN; RECOMBINANT FOWLPOX VIRUS VACCINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA; VIRUS VACCINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; RECOMBINANT VACCINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOWLPOX VIRUS; HEREDITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INNATE IMMUNITY; MALE; PROPHYLAXIS; PROTEIN EXPRESSION; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRUS LOAD; VIRUS RECOMBINANT; GENE VECTOR; GENETICS; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL; SAFETY;

AIDS VACCINES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FOWLPOX VIRUS; GENE PRODUCTS, GAG; GENE PRODUCTS, POL; GENETIC VECTORS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON TYPE II; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAFETY; VACCINES, SYNTHETIC;

EID: 37649006663     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4627     Document Type: Article

References (26)

1. Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV outpatient study investigators. N Engl J Med 1998; 338:853-60.
2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d'Arminio Monforte A, Yust I, Bruun JN, Phillips AN, Lundgren JD. Changing patterns of mortality across Europe in patients infected with HIV-1: EuroSIDA study group. Lancet 1998; 352:1725-30.
3. Cooper DA, Emery S. Therapeutic strategies for HIV infection-time to think hard. N Engl J Med 1998; 339:1319-21.
4. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-30.
5. Pomerantz RJ. Primary HIV-1 resistance: A new phase in the epidemic? Jama 1999; 282:1177-9.
6. Gotch F. Therapeutic vaccines and immunotherapy revisited. J HIV Ther 2005; 10:48-50.
7. Egan MA. Current prospects for the development of a therapeutic vaccine for the treatment of HIV type 1 infection. AIDS Res Hum Retroviruses 2004; 20:794-806.
8. Walker BD, Rosenberg ES. Containing HIV after infection. Nat Med 2000; 6:1094-5.
9. Puls RL, Emery S. Therapeutic vaccination against HIV: Current progress and future possibilities. Clin Sci (Lond) 2006; 110:59-71.
10. Harrer E, Bauerle M, Ferstl B, Chaplin P, Petzold B, Mateo L, Handley A, Tzatzaris M, Vollmar J, Bergmann S, Rittmaier M, Eismann K, Muller S, Kalden JR, Spriewald B, Willbold D, Harrer T. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: Safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther 2005; 10:285-300.
11. Kinloch-de Loes S, Hoen B, Smith DE, Autran B, Lampe FC, Phillips AN, Goh LE, Andersson J, Tsoukas C, Sonnerborg A, Tambussi G, Girard PM, Bloch M, Battegay M, Carter N, El Habib R, Theofan G, Cooper DA, Perrin L. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005; 192:607-17.
12. Jacobson JM, Pat Bucy R, Spritzler J, Saag MS, Eron Jr JJ, Coombs RW, Wang R, Fox L, Johnson VA, Cu-Uvin S, Cohn SE, Mildvan D, O'Neill D, Janik J, Purdue L, O'Connor DK, Vita CD, Frank I. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: The results of AIDS Clinical Trials Group 5068. J Infect Dis 2006; 194:623-32.
13. Kent SJ, Zhao A, Dale CJ, Land S, Boyle DB, Ramshaw IA. A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques. Vaccine 2000; 18:2250-6.
14. Emery S, Workman C, Puls RL, Bloch M, Baker D, Bodsworth N, Anderson J, Crowe SM, French MA, Hoy J, Aichelburg A, Ward LD, Boyle DB, Law MG, Kelleher AD, Cooper DA. Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects. Hum Vaccin 2005; 1:232-8.
15. Clerici M, Berzofsky JA, Shearer GM, Tacket CO. Exposure to human immunodeficiency virus (HIV) type I indicated by HIV-specific T helper cell responses before detection of infection by polymerase chain reaction and serum antibodies [corrected]. J Infect Dis 1991; 164:178-82.
16. Kaul R, Rowland-Jones SL, Kimani J, Dong T, Yang HB, Kiama P, Rostron T, Njagi E, Bwayo JJ, MacDonald KS, McMichael AJ, Plummer FA. Late seroconversion in HIV-resistant Nairobi prostitutes despite preexisting HIV-specific CD8+ responses. J Clin Invest 2001; 107:341-9.
17. McMichael AJ, Ogg G, Wilson J, Callan M, Hambleton S, Appay V, Kelleher T, Rowland-Jones S. Memory CD8+ T cells in HIV infection. Philos Trans R Soc Lond B Biol Sci 2000; 355:363-7.
18. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: What we know, what we don't know, what we should know. Nat Med 2004; 10:806-10.
19. Ammaranond P, Zaunders J, Satchell C, van Bockel D, Cooper DA, Kelleher AD. A new variant cytotoxic T lymphocyte escape mutation in HLA-B27-positive individuals infected with HIV type 1. AIDS Res Hum Retroviruses 2005; 21:395-7.
20. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. Journal of Infectious Diseases 1996; 173:321-9.
21. Kamga I, Kahi S, Develioglu L, Lichtner M, Maranon C, Deveau C, Meyer L, Goujard C, Lebon P, Siner M, Hosmalin A. Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. J Infect Dis 2005; 192:303-10.
22. Loseke S, Grage-Griebenow E, Wagner A, Gehlhar K, AB. Differential expression of IFN-alpha subtypes in human PBMC: Evaluation of novel real-time PCR assays. J Immunol Methods 2003; 276:207-22.
23. Ashton LJ, Carr A, Cunningham PH, Roggensack M, McLean K, Law M, Robertson M, Cooper DA, Kaldor JM. Predictors of progression in long-term non-progressors: Australian long- term nonprogressor study group. AIDS Res Hum Retroviruses 1998; 14:117-21.
24. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, Goedert JJ, Winkler C, O'Brien SJ, Rinaldo C, Detels R, Blattner W, Phair J, Erlich H, Mann DL. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2:405-11.
25. Markowitz M, Jin X, Hurley A, Simon V, Ramratnam B, Louie M, Deschenes GR, Ramanathan Jr M, Barsoum S, Vanderhoeven J, He T, Chung C, Murray J, Perelson AS, Zhang L, Ho DD. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002; 186:634-43.
26. Levy Y, Durier C, Lascaux AS, Meiffredy V, Gahery-Segard H, Goujard C, Rouzioux C, Resch M, Guillet JG, Kazatchkine M, Delfraissy JF, Aboulker JP. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. Aids 2006; 20:405-13.